Gevotroline (WY-47384) is an atypical antipsychotic with a tricyclic structure which was under development for the treatment of schizophrenia by Wyeth-Ayerst. It acts as a balanced modest affinity D2 and 5-HT2 receptor antagonist and also possesses high affinity for the sigma receptor. It was well-tolerated and showed efficacy in phase II clinical trials but was never marketed.
This page contains content from the copyrighted Wikipedia article "Gevotroline"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
